https://pubmed.ncbi.nlm.nih.gov/36566614/
Efficacy and safety of novel dual glucokinase activator dorzagliatin in type-2 diabetes A...
Dorzagliatin has good glycaemic efficacy and well tolerated over 6-months use. Mild increase in body-weight, serum triglycerides and overall adverse events...
efficacy and safety
https://adisinsight.springer.com/trials/700308260?error=cookies_not_supported&code=73420544-0665-43b4-b688-994aabdbf43c
A second phase 1 combination study of Dorzagliatin for the evaluation of the drug PK/PD & drug drug...
https://adisinsight.springer.com/drugsafety/803929422?error=cookies_not_supported&code=48f5f48f-c83e-4e49-9738-47dc3aeb9abb
Dorzagliatin/Empagliflozin - AdisInsight
A patient with type 2 diabetes mellitus and obesity [age and sex not stated] experienced constipation while receiving dorzagliatin and empagliflozin during an
dorzagliatinempagliflozinadisinsight